Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination.
about
An in-depth analysis of original antigenic sin in dengue virus infectionHumans and ferrets with prior H1N1 influenza virus infections do not exhibit evidence of original antigenic sin after infection or vaccination with the 2009 pandemic H1N1 influenza virusResponses to A(H1N1)pdm09 influenza vaccines in participants previously vaccinated with seasonal influenza vaccine: a randomized, observer-blind, controlled study.Characterization of pandemic influenza immune memory signature after vaccination or infection.Individual antibody and T cell responses to vaccination and infection with the 2009 pandemic swine-origin H1N1 influenza virus.Vaccination with drifted variants of avian H5 hemagglutinin protein elicits a broadened antibody response that is protective against challenge with homologous or drifted live H5 influenza virus.The age distribution of mortality due to influenza: pandemic and peri-pandemic.Evaluations for in vitro correlates of immunogenicity of inactivated influenza a H5, H7 and H9 vaccines in humans.Heterotypic humoral and cellular immune responses following Norwalk virus infection.Reproducibility of serologic assays for influenza virus A (H5N1).The wages of original antigenic sin.Original antigenic sin responses to influenza viruses.High preexisting serological antibody levels correlate with diversification of the influenza vaccine responseInfluenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic featuresA new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein.Increased antibodies against unfolded viral antigens in the elderly after influenza vaccination.Immunogenicity and Safety of Trivalent Split Influenza Vaccine in Healthy Korean Adults with Low Pre-Existing Antibody Levels: An Open Phase I Trial.Experimental rabies vaccines for humans.Human influenza vaccines and assessment of immunogenicity.Receptor binding specificity of recent human H3N2 influenza virusesImpact of Pre-exposure History and Host Genetics on Antibody Avidity Following Norovirus Vaccination.From Original Antigenic Sin to the Universal Influenza Virus Vaccine.The Doctrine of Original Antigenic Sin: Separating Good From Evil.Antibody quantity versus quality after influenza vaccination.Age and Influenza-Specific Pre-Vaccination Antibodies Strongly Affect Influenza Vaccine Responses in the Icelandic Population whereas Disease and Medication Have Small Effects.Responders and non-responders to influenza vaccination: A DNA methylation approach on blood cells.
P2860
Q24606493-80B6AE62-8CD4-49B6-80CD-833C774DAC17Q30360439-58D1A0F6-60E4-4B04-81BB-40DB437622EBQ30362883-44D5E90F-92EC-4447-BD61-13E78C6EFE3CQ30363416-F883BEC8-0AF1-4AA0-BF20-6C0D8F41D512Q30404512-F9E3661C-BF31-49BD-864D-0902F81AC294Q30407657-3EFB9038-CBB6-4B34-914B-E88B37B78C27Q30424688-6428E5A6-969F-4566-BA85-458DAFE30EBBQ30424758-F82027F4-BF08-41F8-A8AE-B227D47BF168Q33614589-AE080618-8708-491F-82F7-89E4FA9ACED8Q33628688-EDC42E98-8D23-4C3D-A957-FB95252B7304Q34908157-1813E1A7-FD0A-4EF8-B5CC-048BA332F64FQ34995177-B2A29FF9-887A-41E4-A428-5846B8E0E0D4Q35110980-8271EEAC-A1EE-46B2-9FFC-20A6C6A581A4Q35146181-F5828C62-F4FF-4BEB-AFB5-4BD44016C17EQ36559952-7D767365-4C2B-40F3-AB07-13F6D8B50732Q36631961-D8169080-FF4C-4C32-8A51-9A56732A75B9Q37231850-6AC0AF76-C8B9-493E-926D-1FFAC5CEA79FQ37798009-C2FE155C-67B3-44EA-BAED-92B2D024F47DQ37812125-0905706F-DFE2-49F8-B4B3-0EC5FCA09D5FQ38301903-508346F1-FA10-40A5-9517-471CC7FDC177Q38374766-66BCB698-E40B-4BB1-850A-9F6A596FFCC2Q40059787-7DE32203-379B-4F51-B201-9F269C71693BQ40248207-43352533-40B1-42A1-BE30-AC082FCDD99AQ42589251-9D2DE029-6397-487A-87A7-26F037938D5AQ47550139-2042346E-E5B9-4C0B-BA74-C98F4D4F01DBQ49841152-F7F57ECE-B3FD-4AFB-9AE9-3C322D6A22AC
P2860
Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Amount and avidity of serum an ...... uenza whole-virus vaccination.
@en
Amount and avidity of serum an ...... uenza whole-virus vaccination.
@nl
type
label
Amount and avidity of serum an ...... uenza whole-virus vaccination.
@en
Amount and avidity of serum an ...... uenza whole-virus vaccination.
@nl
prefLabel
Amount and avidity of serum an ...... uenza whole-virus vaccination.
@en
Amount and avidity of serum an ...... uenza whole-virus vaccination.
@nl
P2093
P1433
P1476
Amount and avidity of serum an ...... uenza whole-virus vaccination.
@en
P2093
Kshama Kumari
Upma Gulati
P304
P356
10.1016/J.VACCINE.2004.08.053
P407
P577
2005-02-01T00:00:00Z